A pharmaceutical vehicle which is a nanoemulsion is formulated using 0.1-10 % (w/v) of an oil; 0.1-10% (w/v) of a non-ionic surface active agent; a maximum of 0.01% (w/v) of benzalkonium chloride; a drug or a precursor or active substance; and optionally, one or more of the following components; isotonizing agents, viscosity modifying agents, stabilizers, buffers and/or antioxidants. The vehicle is prepared by emulsification of an aqueous phase which contains a non-ionic surface active agent with an organic phase containing dissolved therein an oil and the drug, drug precursor or active substance in an organic water miscible solvent and then totally removing by evaporation the organic solvent and part of the water up to the final desired volume. The vehicle is especially useful in ophthalmic preparations used to treat eye disorders and diseases.

Compositions for topical ophthalmic application comprising an aqueous mixture of a non-steroidal anti-inflammatory agent. The compositions are formulated with a pH and concentration of agent chosen to maintain at least some of the therapeutic agent of the formulation in suspension.

Topical ophthalmic compositions for treatment of the eye are provided which comprise aqueous mixtures of a non-steroidal agent having a pKa, a pH, and a concentration of agent chosen so as to maintain at least a therapeutic amount of the agent in suspension and a therapeutic amount of the agent in solution. A method for treating diseases of the eye, including inflammation, is also provided by topically applying such aqueous mixtures to eyes in need of treatment, whereby the therapeutic amount of the drug in solution has an immediate therapeutic effect at full concentration, and the therapeutic amount of drug in suspension has a delayed therapeutic effect by release from the suspension over a period of time by reason of dissolution kinetics.

An ophthalmic composition containing a divalent salt and a non-steroidal anti-inflammatory agent as a precipitate. The composition reduces or eliminates the risk of stinging and burning the eye from topical application. Additionally a preservative system comprising a perborate salt, a polyphosphonic acid peroxy stabilizer and EDTA provides stable preservation of a variety of aqueous ophthalmic compositions.

A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, or ionically linked to one another to form a single workings composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may be administered by itself or in the form of a bioerodible or nonbioerodible substance.